CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$13.15
-0.60 (-4.36%)
Open$13.65
Previous Close$13.75
Day High$13.82
Day Low$12.98
52W High$26.95
52W Low$2.54
Volume—
Avg Volume1.48M
Market Cap1.47B
P/E Ratio—
EPS$-0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+245.2% upside
Current
$13.15
$13.15
Target
$45.40
$45.40
$29.32
$45.40 avg
$54.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |
| Rev Growth | +19.0% | -0.6% | +17.7% |
| Debt/Equity | 0.54 | 0.42 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |